148 related articles for article (PubMed ID: 38585276)
21. Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies.
Gao RL; Song J; Sun L; Wu ZX; Yi XF; Zhang SL; Huang LT; Ma JT; Han CB
Front Pharmacol; 2022; 13():920165. PubMed ID: 36034821
[No Abstract] [Full Text] [Related]
22. Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients.
Starzer AM; Berghoff AS; Hamacher R; Tomasich E; Feldmann K; Hatziioannou T; Traint S; Lamm W; Noebauer-Huhmann IM; Furtner J; Müllauer L; Amann G; Bauer S; Schildhaus HU; Preusser M; Heller G; Brodowicz T
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762319
[TBL] [Abstract][Full Text] [Related]
23. Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.
Zhang W; Zhang K; Liu C; Gao W; Si T; Zou Q; Guo Z; Yang X; Li M; Liu D; Mu H; Li H; Yu H; Xing W
Front Immunol; 2023; 14():1127349. PubMed ID: 37180098
[TBL] [Abstract][Full Text] [Related]
24. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
[TBL] [Abstract][Full Text] [Related]
25. Clinical observation of local intervention combined with camrelizumab and apatinib in the treatment of metastatic soft-tissue sarcoma.
Li Y; Li HL; Hu HT; Shao SS; Chen CS; Guo CY; Zhao Y; Yao QJ
J Cancer Res Ther; 2021 Dec; 17(7):1718-1724. PubMed ID: 35381744
[TBL] [Abstract][Full Text] [Related]
26. Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer.
Li L; Liu T; Liu Q; Mu S; Tao H; Yang X; Li Y; Xiong Q; Wang L; Hu Y
Front Pharmacol; 2022; 13():967559. PubMed ID: 36147357
[No Abstract] [Full Text] [Related]
27. Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort.
Gong X; Zhu Y; Zhang Q; Qiu X; Lu C; Tong F; Wang Q; Kong W; Zhou H; Liu B; Zhou Y; Du J
Hum Vaccin Immunother; 2022 Nov; 18(6):2143154. PubMed ID: 36412232
[TBL] [Abstract][Full Text] [Related]
28. PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study.
Chen S; Wei H; Zhao W; Jiang W; Ning R; Zhou S; Tan L; Wang H; Su C; He J; Zeng A; Zhao Y; Yu Q
Front Immunol; 2022; 13():1059995. PubMed ID: 36569915
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer.
Zheng Q; Wu C; Ye H; Xu Z; Ji Y; Rao J; Lu L; Zhu Y; Cheng F
Ann Transl Med; 2021 Oct; 9(20):1568. PubMed ID: 34790774
[TBL] [Abstract][Full Text] [Related]
30. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF
Hamidi S; Iyer PC; Dadu R; Gule-Monroe MK; Maniakas A; Zafereo ME; Wang JR; Busaidy NL; Cabanillas ME
Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606
[No Abstract] [Full Text] [Related]
31. Effectiveness and safety of anti-PD-1 monotherapy or combination therapy in Chinese advanced gastric cancer: A real-world study.
Li T; Liu T; Zhao L; Liu L; Zheng X; Wang J; Zhang F; Hu Y
Front Oncol; 2022; 12():976078. PubMed ID: 36686795
[TBL] [Abstract][Full Text] [Related]
32. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
[No Abstract] [Full Text] [Related]
33. Efficacy and safety of angiogenesis inhibitors plus immune checkpoint inhibitors in advanced soft tissue sarcoma: a real-world, single-center study.
Liu Z; Xu J; Liu M; Hu W; Xu N; Zhu D
Sci Rep; 2023 Feb; 13(1):3385. PubMed ID: 36854710
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study.
Ding X; Liu Y; Zhang Y; Liang J; Li Q; Hu H; Zhou Y
Anticancer Drugs; 2023 Aug; 34(7):877-882. PubMed ID: 36539356
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Efficacy and Safety of Second-Line Treatment Options for Advanced Small-Cell Lung Cancer: A Retrospective Analysis.
Zhao L; Zhao Z; Yan X; Hu X; Feng J; Yu S
Technol Cancer Res Treat; 2024; 23():15330338241227055. PubMed ID: 38258375
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S
Lancet Oncol; 2017 Nov; 18(11):1493-1501. PubMed ID: 28988646
[TBL] [Abstract][Full Text] [Related]
37. A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03).
Procopio G; Claps M; Pircher C; Porcu L; Sepe P; Guadalupi V; De Giorgi U; Bimbatti D; Nolè F; Carrozza F; Buti S; Iacovelli R; Ciccarese C; Masini C; Baldessari C; Doni L; Cusmai A; Gernone A; Scagliarini S; Pignata S; de Braud F; Verzoni E
Tumori; 2023 Feb; 109(1):129-137. PubMed ID: 36447337
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety comparison of PD-1 inhibitors
Yang G; Sun H; Sun N; Huang W; Wang Z; Zhang H; Liu C
J Thorac Dis; 2022 Dec; 14(12):4925-4937. PubMed ID: 36647464
[TBL] [Abstract][Full Text] [Related]
39. Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.
Alessi JV; Wang X; Elkrief A; Ricciuti B; Li YY; Gupta H; Spurr LF; Rizvi H; Luo J; Pecci F; Lamberti G; Recondo G; Venkatraman D; Di Federico A; Gandhi MM; Vaz VR; Nishino M; Sholl LM; Cherniack AD; Ladanyi M; Price A; Richards AL; Donoghue M; Lindsay J; Sharma B; Turner MM; Pfaff KL; Felt KD; Rodig SJ; Lin X; Meyerson ML; Johnson BE; Christiani DC; Schoenfeld AJ; Awad MM
J Thorac Oncol; 2023 Nov; 18(11):1524-1537. PubMed ID: 37247843
[TBL] [Abstract][Full Text] [Related]
40. [Retrospective study on the efficacy and safety of low dose apatinib in reversing chemotherapy resistance in sarcoma].
Ye T; Yuan SY; Fan L; Feng LW; Chen YT; Chen J
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2435-2440. PubMed ID: 36000372
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
